329. 無虹彩症 Aniridia Clinical trials / Disease details
臨床試験数 : 3 / 薬物数 : 2 - (DrugBank : 2) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04117880 (ClinicalTrials.gov) | December 31, 2018 | 19/9/2019 | A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia | Nonsense Mutation Aniridia: An Ataluren (PTC124) Phase 2 Extension Study | Aniridia | Drug: Ataluren | PTC Therapeutics | NULL | Withdrawn | 2 Years | N/A | All | 0 | Phase 2 | NULL |
2 | NCT02647359 (ClinicalTrials.gov) | January 31, 2016 | 29/12/2015 | Study of Ataluren in Participants With Nonsense Mutation Aniridia | STAR: A Phase 2, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia | Aniridia | Drug: Ataluren;Drug: Placebo | PTC Therapeutics | NULL | Completed | 2 Years | N/A | All | 39 | Phase 2 | United States;Canada |